Arvinas to Participate in Upcoming Investor Conferences
03 Juni 2024 - 10:30PM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced that management will participate in
two upcoming investor conferences:
- Jefferies Global Healthcare Conference on
Thursday, June 6 in New York City.
- John Houston, Ph.D., Chairperson, Chief Executive Officer and
President, and Noah Berkowitz, M.D., Ph.D., Chief Medical Officer,
will participate in a fireside chat. A live audio webcast of the
presentation will be available here and on the Events +
Presentations section of the Company’s website.
- Goldman Sachs 45th Annual Global Healthcare
Conference on Monday, June 10 in Miami.
- John Houston, Ph.D., Chairperson, Chief Executive Officer and
President, and Noah Berkowitz, M.D., Ph.D., Chief Medical Officer,
will participate in a fireside chat. A live audio webcast of the
presentation will be available here and on the Events +
Presentations section of the Company’s website.
About ArvinasArvinas is a clinical-stage
biotechnology company dedicated to improving the lives of patients
suffering from debilitating and life-threatening diseases through
the discovery, development, and commercialization of therapies that
degrade disease-causing proteins. Arvinas uses its proprietary
PROTAC® Discovery Engine platform to engineer proteolysis targeting
chimeras, or PROTAC® targeted protein degraders, that are designed
to harness the body’s own natural protein disposal system to
selectively and efficiently degrade and remove disease-causing
proteins.
In addition to its robust preclinical pipeline of PROTAC protein
degraders against validated and “undruggable” targets, the company
has three investigational clinical-stage programs currently
enrolling: vepdegestrant for the treatment of patients with locally
advanced or metastatic ER+/HER2- breast cancer; ARV-102 for the
treatment of patients with neurodegenerative disorders, and ARV-393
for the treatment of patients with relapsed/refractory non-Hodgkin
Lymphoma and potentially other lymphomas.
In April 2024, Arvinas entered into a transaction with Novartis,
including a global license agreement for the development and
commercialization of the clinical stage PROTAC® androgen receptor
protein degrader ARV-766 for the treatment of prostate cancer. The
transaction closed in May 2024. For more information, visit
www.arvinas.com.
Contacts
Investors:Jeff Boyle+1 (347)
247-5089Jeff.Boyle@arvinas.com
Media:Kathleen Murphy+1 (760)
622-3771Kathleen.Murphy@arvinas.com
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
Von Sep 2023 bis Sep 2024